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Abstract
The adaptive and innate branches of the vertebrate immune system work in close collaboration to protect
organisms from harmful pathogens. As an organism ages its immune system undergoes immunosenescence,
characterized by declined performance or malfunction in either immune branch, which can lead to disease
and death. In this study we develop a mathematical model of the immune system that incorporates both
the innate and adaptive immune compartments, named the integrated immune branch (IIB) model, and
investigate how immune behavior changes in response to a sequence of pathogen encounters. We find that
repeated pathogen exposures induce a fragility, in which exposure to novel pathogens may cause the immune
response to transition to a chronic inflammatory state. The chronic inflammatory state of the IIB model is
qualitatively consistent with “inflammaging,” a clinically-observed condition in which aged individuals expe-
rience chronic low-grade inflammation even in the absence of pathogens. Thus, the IIB model quantitatively
demonstrates how immunosenescence can manifest itself in the innate compartment as inflammaging. In
particular, the onset of a persistent inflammatory response strongly depends on the history of encountered
pathogens; the timing of its onset differs drastically when the same set of infections occurs in a different
order. Lastly, the coupling between the two immune branches generates a trade-off between rapid pathogen
clearance and a delayed onset of immunosenescence. By considering complex feedbacks between immune
compartments, our work suggests potential mechanisms for immunosenescence and provides a theoretical
framework to account for clinical observations.
Keywords: immunosenescence, innate and adaptive immune responses, computational and systems
biology, mathematical modeling
1. Introduction
Infectious diseases as diverse as bacterial pneumonia, influenza, tuberculosis, herpes zoster, and most
recently COVID-19 have an increased morbidity and mortality among the elderly [1, 2, 3, 4, 5, 6]. Especially
in conjunction with global demographics that broadly reflect increases in age across the world’s populations
(both due to prolonged life expectancy and declining birth rates), the prevalence of disease among the elderly
underscores the need for a better understanding of how physiology changes with age [7]. In particular, it
is acutely important to identify the causes of immunosenescence, the readily observed yet mechanistically
vague deterioration of immune function in aged individuals.
The vertebrate immune system targets and clears pathogens through the collaborative efforts of innate
and adaptive immune responses: the innate immune system reacts quickly and non-specifically to pathogenic
threats, while the adaptive immune system acts more slowly and generates a pathogen-specific response
through clonal expansion of cognate T and B lymphocytes. To orchestrate this division of responsibility,
extensive bidirectional interactions exist between the innate and adaptive immune compartments [8, 9, 10, 11,
12, 13]. For example, dendritic cells in the innate compartment mediate the presentation of antigens to the
adaptive compartment [14]. Conversely, T cells in the adaptive arm reduce the production of inflammatory
cytokines and thus limit tissue damage caused by the innate immune response [15, 16, 17]. For example,
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experiments with nude mice (a mutant mouse strain with low T cell levels) showed that death can ensue
without this adaptive suppression of inflammation [16, 17].
Immunosenescence manifests itself in both the innate and the adaptive immune branches. In the adaptive
branch aging is partially driven by thymus involution, which reduces the output of new naive T cells [18, 19,
20]. Furthermore, a lifetime of persistent pathogen exposures (e.g. chronic infections like cytomegalovirus)
leads to oligoclonal expansion of memory T cells specific to those pathogens. These physiological mechanisms
lead to an “imbalanced” repertoire of immune cells that is predominately populated by memory cells specific
to frequently encountered pathogens, which limit the ability of the adaptive branch to respond to novel
pathogens. Indeed, the increased fraction of CD8+ T cells caused by memory inflation has been associated
with the immune risk phenotype (IRP), which has been found to predict impaired immune function and
mortality [21, 22, 23].
In the innate compartment, aging is associated with the development of a chronic low-grade inflammatory
response even in the absence of pathogen stimulation, called “inflammaging” [24]. The elderly often experi-
ence chronic inflammation and possess elevated levels of pro-inflammatory cytokines [23, 25, 26, 27], which
have been found to be strong predictors of mortality (for example, interleukin 6 has been associated with
the IRP) [23]. Prior theories suggest that inflammaging is facilitated by long-lasting pathogen encounters,
cell debris and stress, and the reduced efficiency of the adaptive immune response [24, 28, 29]. Still, the
mechanisms underlying the onset of inflammaging— and in particular its connection to aging in the adaptive
immune system— require further study.
In an earlier mathematical model of the adaptive immune response, Stromberg and Carlson found that
repeated pathogen exposures could lead to an imbalanced immune repertoire that was vulnerable to rare
pathogens [30]. Around the same time, Reynolds et al. developed a model of the innate immune response
immediately following a pathogen encounter. Based on these earlier models, in this paper we construct a
mathematical model of the coupled innate-adaptive immune system called the integrated immune branch
(IIB) model, and demonstrate how immunosenescence can develop and trigger a chronic inflammatory re-
sponse. Here, as in the earlier adaptive immune model, the onset of immunosenescence arises purely from
an imbalanced immune repertoire, and occurs without any further assumptions regarding the degradation
of cellular function with age. The IIB model explicitly incorporates the inflammatory response of the in-
nate branch, T cell dynamics of the adaptive branch, and innate-adaptive crosstalk. It recapitulates several
clinically-observed signatures of immunosenescence: the ratio of naive to memory cells decreases over time
[31], repeated exposure to chronic infections (e.g. human cytomegalovirus) induces immune fragility [32],
and this fragility is characterized by chronic inflammation (“inflammaging”) [31, 23].
With the IIB model, we first characterize the dynamics and steady states of the immune system in
response to a single infection event. Then, the system is exposed to a series of pathogens that form an
infection history. This sequence of infection events causes overspecialization in the adaptive compartment and
triggers chronic inflammation. In particular, the order in which infections are encountered strongly influences
health outcomes, and can hasten or delay the onset of chronic inflammation. Further, by tuning resource
allocation in the adaptive compartment toward pathogen clearance versus suppression of inflammation,
crosstalks between immune compartments may be directly manipulated. This manipulation reveals a trade-
off between a delayed onset of chronic inflammation and rapid pathogen clearance. Our model provides a
mechanistic explanation of how accumulated pathogen exposures can cause immune fragility that leads to
inflammaging and immunosenescence, and may serve as a foundation for quantitative studies of immune
crosstalk and aging.
2. Mathematical model
Extensive mathematical and computational modeling efforts have been made to better understand both
the innate and adaptive branches of vertebrate immune system [34, 35, 36]. Additionally, a rich literature
exists regarding the inflammatory innate response [37, 38, 39, 40, 41] and the adaptive immune repertoire
[42, 43, 44, 45]. In particular, Reynolds et al. studied the positive feedback between activated phagocytes
and collateral tissue damage [33], and Stromberg and Carlson modeled the accumulated loss of memory cell
diversity over the course of a lifetime of infections [30]. In this study, we modify and synthesize the models of
Reynolds et al. and Stromberg and Carlson to develop an integrated immune branch (IIB) model, in which
the innate and adaptive immune branches work collaboratively to clear pathogens.
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Figure 1: Schematic of the integrated immune branch (IIB) model. An introduced pathogen prompts innate
and adaptive immune responses that seek to eliminate the pathogen. The innate response (green) is adapted from
the model of Reynolds et al. [33], in which the presence of a pathogen activates phagocytes that induce inflammation
and the subsequent production of anti-inflammatory cells. The adaptive immune response (magenta) is adapted from
the model of Stromberg and Carlson [30], in which presented pathogens (orange) activate naive and memory T cells
specific to that pathogen, causing them to divide into effector cells that target the pathogen. In this model, the
delay in the adaptive response due to antigen presentation is hard-coded via the compartments P
(1)
i , P
(2)
i , and P
(3)
i
using the linear chain technique. The state variables of this model are described in Table 1, the model itself is given
explicitly in Table 2, and the parameters of this model are provided in Table 3.
A schematic of the IIB model is depicted in Fig. 1, and a thorough accounting of the individual components
of the innate (pathogen Pi, phagocytes N
∗, tissue damage D, and anti-inflammatory cytokines CA) and
adaptive (pathogen Pi, naive cells Ni, memory cells Mi, and effector cells Ei) models is provided in Table
1. The coupled model is described in full in Table 2, and parameter descriptions and values are provided in
Table 3. For more complete descriptions of the separate innate and adaptive immune models, we refer the
reader to the original publications [33, 30].
2.1. Innate immune response
In the model formulated by Reynolds et al. [33] (depicted in the green box of Fig. 1), once a pathogen
Pi is introduced, phagocytes N
∗ (which include, e.g., neutrophils and macrophages) are recruited to the
site of the infection by activation or migration. These phagocytes kill the pathogen Pi by phagocytosis,
degranulation, or by creating neutrophil extracellular traps. At the same time, these phagocytes release
inflammatory cytokines that induce inflammation and tissue damage D in the host. Damaged tissue in turn
releases additional inflammatory cytokines, further promoting phagocyte activation. Following this initial
inflammatory response, a wave of anti-inflammatory cytokines CA is released to downregulate phagocyte
recruitment and to reduce inflammation and tissue damage.
The steady-state behavior of this model was investigated by Reynolds et al. [33], who found that this
formulation of the innate immune response led to three possible steady states: health, in which the pathogen
is cleared and the phagocytes and tissue damage vanish; septic death, in which the innate response is unable
to clear the pathogen; and chronic inflammation, in which the innate response clears the pathogen at the
expense of inducing a constant inflammatory response that fails to dissipate, even after pathogen clearance.
In the model’s original formulation this chronic inflammation steady state was named aseptic death, but
in this paper we allow for the possible interpretation of this steady state as “inflammaging,” which is not
necessarily fatal, rather than death [46, 47]. As we will show, the IIB model retains these three steady states
while introducing interplay between the non-specific innate response and the specific adaptive response.
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Notation Immune component Description
Pi Pathogen • Harmful exogenous stimulants (e.g., bacteria or viruses) that
activate an immune response
• Pathogen of shape i (shape space formulation)
N∗ Activated
phagocytes
• Phagocytes (which include neutrophils and macrophages) that are
activated by any pathogen Pi or by pro-inflammatory cytokines
• Responsible for removing pathogens Pi, but cause collateral tissue
damage D
D Tissue damage • Caused by activated phagocytes N∗
• Causes release of pro-inflammatory cytokines that recruit additional
phagocytes N∗
CA Anti-inflammatory
cytokines
• Small protein molecules that reduce the efficiency and recruitment
of activated phagocytes N∗
• Production encouraged by activated phagocytes N∗ and tissue dam-
age D, and also by effector cells E (innate-adaptive crosstalk)
Ni Naive cells • Mature T cells with receptor specificity represented by shape i that
are agnostic to previous pathogen encounters
• Divide and differentiate into memory Mi and effector Ei cells when
activated by pathogens Pi
• Subject to homeostasis control mechanisms
Mi Memory cells • Long-lived cells differentiated from naive cells Ni with the same
pathogen specificity
• Divide and differentiate into memory Mi and effector Ei cells when
activated by pathogens Pi
• Subject to homeostasis control mechanisms
Ei Effector cells • Short-lived cells differentiated from naive Ni and memory Mi cells
• Remove pathogen Pi and produces anti-inflammatory cytokines CA
Table 1: Major biological components in the integrated immune branch (IIB) model. Model equations
are provided in full in Table 2.
2.2. Adaptive immune response
The IIB model also incorporates the adaptive immune response (shown in the magenta box of Fig. 1),
which is based on the shape-space adaptive immune model of Stromberg and Carlson [30]. By assigning
discrete “shapes” to pathogen epitopes and adaptive immune cells, this formulation allows pathogen-specific
immune memory and immune responses to be developed [48]. Thus, an introduced pathogen Pi of shape
i induces an adaptive response consisting of naive cells Ni, memory cells Mi, and effector cells Ei that
all specifically target the introduced pathogen. There are Smax available shapes. In the original model of
Stromberg and Carlson, pathogens Pi of shape i could interact with adaptive cells of some different shape
j with a lowered binding affinity, but in this paper for computational efficiency we require that adaptive
responses be activated by a pathogen of identical shape.
The process of antigen presentation delays the activation of the adaptive immune response. This phe-
nomenon is encoded in the IIB model with the linear chain technique (shown in the orange box of Fig. 1), in
which the populations P
(1)
i , P
(2)
i , and P
(3)
i are intermediate states during antigen presentation [49]. Even-
tually, the presented antigen P
(3)
i induces naive cells Ni to divide into memory cells Mi and effector cells Ei;
and memory cells Mi to divide into additional memory cells Mi and effector cells Ei. Once created, these
pathogen-specific effector cells Ei work to clear the pathogen Pi.
2.3. Integrated immune branch (IIB) model
The IIB model is described in full in Table 2, with descriptions and values of the parameters given
in Table 3. Next, we emphasize the modifications that synthesized the two separate innate and adaptive
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Equation Interpretation
dPi
dt
= kpgPi
(
1− |
#»
P |
P∞
)
− kpmsm
µm + kmp| #»P |
Pi
− kpnf(N∗)Pi − pγPiEi −∆ ∗ Pi
Pathogen Pi of shape i changes according to:
• logistic growth, carrying capacity P∞ (|·| denotes the 1-norm)
• inhibition by a non-local immune response
• clearance by innate phagocytes N∗, effect is mediated by anti-
inflammatory cytokines CA via f(·)
• clearance by adaptive effector cells Ei
• sequestration by dendritic cells for antigen presentation
dP
(1)
i
dt
= ∆
[
Pi − P (1)i
]
dP
(2)
i
dt
= ∆
[
P
(1)
i − P (2)i
]
dP
(3)
i
dt
= ∆
[
P
(2)
i − P (3)i
]
− βγP (3)i (Ni +Mi)
• antigen presentation occurs with hard-coded delay (linear
chain technique) of 3/∆ units of time on average required
for a pathogen Pi to transition to compartment P
(3)
i
• compartments P (1, 2, 3)i correspond to intermediate states
during antigen presentation
• once antigen arrives in compartment P (3)i it activates naive
cells Ni and memory cells Mi
dNi
dt
= −αγNiP (3)i + θN − δNNi
| # »M |+ | #»N |
R0
Naive cells Ni of shape i change according to:
• division into effector cells Ei (with rate f) and memory cells
Mi (with rate 1− f)
• constant production at rate θN
• return to homeostatic equilibrium (timescale 1/δN )
dMi
dt
= (2− 2f)αγNiP (3)i
+ (1− 2f)αγMiP (3)i − δMMi
| # »M |+ | #»N |
R0
Memory cells Mi of shape i change according to:
• division into effector cells Ei (with rate f) and memory cells
Mi (with rate 1− f)
• growth from naive and memory cell division
• decay at rate δM
dEi
dt
= 2fα(Mi +Ni)γP
(3)
i − δEEi
Effector cells Ei of shape i change according to:
• production by naive and memory cells proportional to antigen
presentation rate α
• decay at rate δE
dN∗
dt
=
snrR
µnr +R
− µnN∗
Innate phagocytes N∗ change according to:
• activation by the presence of other phagocytes, pathogen, or
tissue damage (encapsulated by R)
• decay at rate µn
dD
dt
= kdnfs(f(N
∗, CA))− µdD
Tissue damage D changes according to:
• induced by activated phagocytes N∗, but ameliorated by the
presence of anti-inflammatory cytokines CA via f(·)
• decay at rate µd
dCA
dt
= sc + kcn
f(N∗ + kcndD, CA)
1 + f(N∗ + kcndD, CA)
− µcCA
+ (1− p) kce |
#»
E|
| #»E|+ E1/2
Anti-inflammatory cytokines CA change according to:
• production at constant rate sc
• production related to phagocyte and tissue damage levels
• decay at rate µc
• stimulation by effector cells | ~E|
R = f(knnN
∗ + knpP + kndD)
f(x, CA) =
x
1 +
(
CA
C∞
)2
fs(y) =
y6
x6dn + y
6
• R is an aggregation of signals that trigger the innate immune
response
• f(x, CA) mediates the value of x according to the level of
anti-inflammation cytokines CA
• fs(y) was phenomenologically fit by Reynolds et al. in their
original formulation [33]
Table 2: Full equations of the integrated immune branch (IIB) model that govern the dynamics of the
immunological state variables described in Table 1. A full list of parameter values and descriptions is given
in Table 3
.
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Parameter Value Description Source Parameter Value Description Source
kpg 0.6 pathogen logistic growth rate [33] P∞ 20 pathogen logistic carrying
capacity
[33]
kpm 0.6 pathogen clearance rate by
nonspecific response
[33] sm 0.005 source rate of nonspecific
response
[33]
µm 0.002 decay rate of nonspecific
response
[33] kmp 0.01 rate of nonspecific exhaustion
due to pathogen
[33]
kpn 1.8 rate of pathogen clearance by
innate response
[33] γ 0.02 binding affinity between
pathogens and adaptive cells
of the same type
[30]
p 0.9 proportion of effector cell
resources allocated to
pathogen clearance
∆ 0.1 rate of antigen presentation
β 0.01 rate of P
(3)
j depletion by
antigen presentation
α 0.1 activation rate of adaptive
cells by antigen presentation
[30]
θN 5 naive cell creation rate R0 7200 total naive and memory cell
logistic carrying capacity
δN 0.025 naive cell homeostasis rate δM 4e-5 memory cell decay rate
f 0.4 proportion of memory and
naive cells that divide into
effector cells
[30] δE 0.05 effector cell decay rate [30]
snr 0.08 maximum phagocyte
recruitment rate
[33] µnr 0.12 phagocyte recruitment
half-saturation constant
[33]
µn 0.05 phagocyte decay rate [33] kdn 0.35 rate of tissue damage due
to phagocytes
[33]
µd 0.02 tissue damage decay rate [33] sc 0.0125 source rate of
anti-inflammatory cytokines
[33]
kcn 0.04 maximum activation of
anti-inflammatory cytokines
by phagocytes and tissue
damage
[33] kcnd 48 conversion rate between
tissue damage and phagocyte
abundance
[33]
µc 0.1 anti-inflammatory cytokine
decay rate
[33] knn 0.01 conversion rate between
phagocyte abundance and
aggregate innate response R
[33]
knp 0.1 conversion rate between
pathogen abundance and
aggregate innate response R
[33] knd 0.02 conversion rate between
tissue damage and aggregate
innate response R
[33]
kce 0.4 maximum anti-inflammatory
cytokine production rate by
effector cells
E1/2 10 half-saturation constant for
cytokine production by
effector cells
C∞ 0.28 scaling factor for
anti-inflammatory cytokine
abundance
[33] xdn 0.06 phenomenologically-inferred
half-saturation constant
[33]
Smax 36 number of pathogen shapes in
shape space
[30]
Table 3: Typical parameters of the immune model in Table 2. The parameters listed in this table are used to
generate Fig. 5, while the other figures are created with slightly modified parameters as detailed in the Supplementary
Information. Most innate parameters were originally described in the Reynolds et al. model [33], while most adaptive
parameters were originally described in the Stromberg and Carlson model [30]. Parameter values that are the same
as those used in the original models are bold-faced.
immune models.
In the IIB model, the innate and adaptive components are linked in two ways. First, the two compart-
ments are implicitly linked through the pathogen population: a higher pathogen load Pi not only activates
more phagocytes N∗ in the innate compartment, but also leads to a higher rate of antigen presentation and
subsequent activation of naive Ni, memory Mi, and effector Ei cells. Thus, depletion of pathogen by either
response (by phagocytes N∗ or by effector cells Ei) affects both compartments.
Second, the two compartments are explicitly linked since effector cells Ei can create anti-inflammatory
cytokines CA that weaken the innate response. The suppression of inflammatory responses by effector
cells has been observed experimentally [15, 16, 17]. In the IIB model, effector cells are allocated either
to clear pathogens or to promote the production of anti-inflammatory cytokines, in proportion to p and
1 − p, respectively (dashed line in Fig. 1). The pathogen removal efficiency p may be varied from 0 to 1,
so that in the limit that effector cells are solely responsible for pathogen clearance (p = 1) no additional
anti-inflammatory cytokines are produced. Therefore, the synthesized model is capable of quantitatively
comparing the two adaptive immune functions of pathogen clearance and inflammation attenuation.
The IIB model introduces homeostatic constraints that regulate the capacity of naive and memory cells.
The rates of both homeostatic responses are dependent on the sum of the bulk naive cell population | ~N | ≡
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Figure 2: Pathogen abundance (orange, solid) is regulated by the innate and adaptive immune responses
in the IIB model. The clearance rates of the innate response (green dash-dotted, rate given by kpnf(N
∗)Pi) and
the adaptive response (purple dashed, rate given by pγPiEi), as described in the
dPi
dt
equation of Table 2, are plotted.
The innate response is activated immediately, while the adaptive response is delayed due to the antigen presentation
process (encoded with the linear chain technique Pi → P (1)i → P (2)i → P (3)i ). Ultimately the combined immune
responses manage to clear the pathogen. The parameters used to generate this figure are given in Table 3 and in
Table S1 of the Supplementary Information.
∑
iNi and the bulk memory cell population | ~M | ≡
∑
iMi. In the process of clearing a pathogen, memory
cells accumulate. Afterwards, to satisfy the homeostatic constraints, naive cells must become less abundant
than they were before the infection. In the Supplementary Information, we derive analytic approximations to
the immune dynamics that are generated by these homeostatic relaxations; when the timescale of pathogen
clearance is much shorter than the timescale of homeostatic relaxation, these expressions can be used as part
of a dynamic programming approach to significantly speed up numerical simulations.
3. Results
3.1. Clearance of a single infection by the coupled immune response
In the IIB model, once a pathogen is introduced it initiates a cascade of immune responses in the innate
and adaptive compartments, and these responses combat the logistic growth of the pathogen and attempt
to drive it to extinction. Fig. 2 depicts a representative pathogen encounter and clearance, and plots the
pathogen abundance (orange) as well as the pathogen clearance rates due to the adaptive effector cell (purple)
and innate phagocyte (green) responses given by the quantities pγPiEi and kpnf(N
∗)Pi, respectively, as given
in Table 2. Note that the adaptive response is specific to the pathogen shape, while the innate response is
nonspecific. For clarity only the lumped contributions of the innate and adaptive compartments to pathogen
clearance are plotted in Fig. 2. The populations of every immunological variable are plotted for several
scenarios in Fig. 3.
In Fig. 2 the logistic growth of the pathogen drives the initial pathogen spike, which is mildly tempered
by a non-local immune response as described by Reynolds et al. [33]. Phagocytes are immediately recruited
and attack the pathogen, leading to the increase in innate pathogen clearance (green). Simultaneously, the
collateral tissue damage inflicted by phagocytes causes the production of anti-inflammatory cytokines, which
suppress further phagocyte recruitment and tissue damage. Anti-inflammatory cytokines in conjunction with
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a decreasing pathogen population cause the decrease in innate pathogen clearance. Once the pathogen is
presented to the adaptive immune branch— a delay that is hard-coded in the IIB model with the auxiliary
immunological variables P
(1)
i , P
(2)
i , and P
(3)
i — the naive and memory cells specific to the presented antigen
divide into effector cells. These effector cells subsequently contribute to the increase in adaptive pathogen
clearance (purple). Ultimately, with the given parameter values (provided in the Supplementary Information)
the innate and adaptive responses overpower the pathogen and drive it to extinction. In the process, memory
cells specific to this pathogen shape proliferate and provide future protection in case the same pathogen is
faced again in the future, since the higher initial abundance of pathogen-specific memory cells will result in
a more immediate adaptive response.
3.2. Steady state analysis of the IIB model
The IIB model described in Table 2 exhibits steady states when the time derivatives of all the populations
vanish. This coupled model inherits many of the steady state characteristics of the constituent innate and
adaptive immune models. In particular, this model exhibits steady states of (a) health, characterized by
vanishing pathogen and immune response; (b) chronic inflammation, in which the pathogen clears but the
innate immune response is sustained in a positive feedback loop; and (c) septic death, characterized by the
chronic presence of pathogen and activated immune responses. Realizations of these three steady states are
displayed in Fig. 3, and the parameter sets used to generate each outcome are provided in Table 3 and in
Table S1 of the Supplementary Information. In Fig. 4, phase diagrams demonstrate how different parameter
regimes and initial conditions lead to different steady states. To observe the presence of these steady states
mathematically, note that a quantity Pi may be factored out of the pathogen dynamics
dPi
dt , from which it
is clear that at steady state the pathogen population P¯i must either be 0 or some nonzero quantity that
satisfies 1Pi
dPi
dt = 0. The three steady states immediately follow from the implications of choosing P¯i to be
zero or non-zero.
(a) Health steady state— If P¯i = 0 at equilibrium, then the intermediate pathogen states must vanish as
well (P¯
(1)
i = P¯
(2)
i = P¯
(3)
i = 0). In the absence of presented antigen, the memory cells Mi decay with timescale
1/δM . When this timescale is slow relative to the homeostatic dynamics of the naive cells (whose dynamics
are of timescale 1/δN ), the naive cells Ni tend towards their homeostatic equilibrium N¯i as described in
Eq. (S11) in the Supplementary Information. Lastly, all effector cells Ei decay with timescale 1/δE , which
is assumed to be fast compared to the naive and memory cell dynamics. Thus, in the absence of pathogen,
the adaptive immune response turns off and becomes dormant. In a steady state with P¯i = 0 the innate
immune response can either be “inactive” or it can be “active,” which lead to the steady states of health or
chronic inflammation, respectively. When the innate immune response is inactive, the activated phagocytes
N∗ and tissue damage D are both zero. This implies that the aggregate innate response R is zero as well.
Lastly, in the absence of the innate response and effector cells, anti-inflammatory cytokines equilibrate to
a constant level. It is straightforward to check that setting P¯i = N¯
∗ = D¯ = 0 and C¯A = sc/µc leads to a
steady state in this model.
This health steady state is demonstrated numerically in Fig. 3a. In this figure, an initial pathogen
response activates innate (green) and adaptive (purple) responses that eventually vanish. The naive and
memory cells change over the course of the adaptive immune response, and then remain at constant steady
state values.
(b) Chronic inflammation steady state— When P¯i = 0 but the innate immune response is active, the
model reaches the chronic inflammation steady state. This steady state is inherited from the Reynolds et
al. innate immune model [33], and occurs due to a positive feedback loop between tissue damage D and
phagocytes N∗ (as can be schematically understood based on Fig. 1). In particular, there exist equilibrium
quantities N¯∗ and D¯ that precisely balance the activation of phagocytes and accumulation of tissue damage
with their respective decays µnN¯
∗ and µdD¯. This chronic inflammation steady state is shown in Fig. 3b:
the pathogen is cleared and effector cells dissipate, but the innate response is perpetually sustained.
(c) Septic death steady state— Lastly, the steady state in which the pathogen population is sustained is
called septic death. For a steady state with nonzero pathogen P¯i, the values of the intermediate pathogen
states P¯
(1)
i , P¯
(2)
i , and P¯
(3)
i will be nonzero as well. Subsequently, the presented pathogen P¯
(3)
i sustains the
activation of naive, memory, and effector cells. In the innate compartment, the nonzero pathogen presence
implies a nonzero aggregate innate response R¯, which implies a nonzero equilibrium population of phagocytes
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Figure 3: The IIB immune model exhibits (a) health, (b) chronic inflammation, and (c) septic death
steady states. Components of the adaptive response are plotted in purple, while components of the innate response
are plotted in green. (a) An inoculated pathogen activates phagocytes, which in turn induce tissue damage. Following
antigen presentation, naive cells divide into memory cells and effector cells. The phagocytes and effector cells jointly
suppress the pathogen, which goes extinct, and the tissue damage gradually decays resulting in the health steady
state. (b) The innate and adaptive immune responses clear the pathogen, but in the process the innate response enters
a positive feedback loop between phagocyte recruitment and tissue damage leading to persistent tissue damage and
phagocyte activation, called the chronic inflammation steady state. (c) The innate and adaptive immune responses
do not clear the pathogen, leading to the septic death steady state characterized by the presence of pathogen and
tissue damage. The chronic inflammation steady state was obtained with smaller innate clearance rate kpm and
smaller tissue damage decay rate µd than were used to obtain the health steady state. The septic death steady state
was obtained with a larger proportion of cognate cells that divide into effector cells f and a larger pathogen growth
rate kpg than were used to obtain the health steady state. Explicit values of the parameters used for each panel are
given in Table 3 and in Table S1 of the Supplementary Information.
N¯∗, which in turn implies a nonzero equilibrium population of tissue damage D¯. Therefore, the septic death
steady state is characterized by activity in both the innate and the adaptive immune compartments. Naive
and memory cells of the adaptive compartment continue to predominantly divide into effector cells; eventually
all adaptive cells are exhausted and vanish while failing to clear the pathogen. This steady state is depicted
in Fig. 3c.
The rest of this paper uses a parameter regime that does not exhibit the septic death steady state: in
particular, simulations of this paper set f (the proportion of cognate cells that divide into effector cells)
equal to 0.4, which causes memory cells to accumulate until they are able to produce enough effector cells
9
Naive cell IC
M
em
or
y 
ce
ll 
IC
0 100 200
200
100
300
400
0
Naive cell IC
0 100 200
200
100
300
400
0
Naive cell IC
0 100 200
200
100
300
400
0
0 50 100 150 200
Naive cell IC
0
100
200
M
em
or
y 
ce
l
50 100 150
Naive cell IC
0
100
200
M
em
or
y 
c
50 100 150 200400
Health Chronic inflammation Septic death
Figure 4: Phase diagram of immunological steady states as a function of naive cell and memory cell
initial conditions (ICs). In IIB model, the immune system can reach health, chronic inflammation, or septic death
steady state following a pathogen encounter, depending on the level of cognate naive and memory cells when the
pathogen is introduced. The proportion f of cognate cells that divide into effector cells significantly influences the
steady state phase diagram and septic death can only occur when f ≥ 0.5 (also see main text). Results are calculated
in the absence of homeostatic response (θN = δN = δM = 0 in Table 2) during single infection events and initial
pathogen level is Pi = 1. Other parameters for generating the phase diagrams are as stated in Table 3. Except in
current figure, f = 0.4 is always used in this study.
to suppress the pathogen. When f is larger than 0.5 memory cells deplete over the course of an immune
response, which can lead to septic death. A phase diagram of steady state behaviors at different values
of f for different naive and memory cell initial conditions is plotted in Fig. 4. In the following text, we
focus on the transition from health to chronic inflammation, a process that is phenomenologically similar to
inflammaging.
3.3. The onset of chronic inflammation results from a lifetime of infections
Next we consider the immunological consequences that result from encountering a sequence of infection
events. Infection sequences are composed of discrete infection events, and each infection event consists of
the time course following the encounter with a particular pathogen shape until a steady state of the system
(i.e. health, chronic inflammation, or septic death) is reached. For each infection event an immune response
is generated by simulating the IIB model, given in Table 2. When pathogen encounters are evenly spaced
in time, the number of infection events acts as a measure of age. This infection sequence encodes a lifetime
of infection events, is different for different individuals, and serves as a vehicle with which to explore the
variable immunological outcomes experienced by different individuals over their lifetimes.
More concretely, the IIB model is simulated for ntot infections that are ∆T = 1000 time units apart. The
time ∆T is chosen to be sufficiently large so that the system reaches a steady state between infection events
(i.e., infection events are well separated in time). The shape space in the IIB model is discrete, consisting of
Smax = 36 available pathogen shapes. For each infection event, the probability pi that a pathogen of shape
i is encountered is given by
pi = ζe
−i/ξ, i = 1, 2, . . . , Smax, (1)
where ξ = 20/3 and ζ satisfies
∑Smax
i=1 pi = 1. This distribution allows for some pathogen shapes to be
more common than others, and is similar to the one originally used by Stromberg and Carlson [30]. A
lifetime of infections is explicitly encoded in the infection sequence {S`}, where each S` is the pathogen
shape encountered for the `th infection event. Then, for each infection event ` = 1, 2, . . . , ntot, a single unit
of pathogen PS` is added to the system at time t` = 1000(`−1). In the simulations used to create Figs. 5, 6,
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Figure 5: Timing of the transition to chronic inflammation (CI) is highly variable and depends on
previous pathogen encounters. (a, b) Activity of the innate (green) and adaptive (purple) immune responses
over the course of 100 infection events for two different infection sequences drawn from the same statistical distribution.
As a proxy for these responses, the average number of effector cells 〈E〉 ≡ 1
∆T
∫ t`+1
t`
| ~E(t)| dt and phagocytes 〈N∗〉 ≡
1
∆T
∫ t`+1
t`
N∗(t) dt for each infection event ` are plotted. The sharp transitions indicate the onset of the chronic
inflammation state, and occur at the 57th and 82nd infection events, respectively. (c) An ensemble average of
the innate and adaptive immune responses over 1000 infection sequences (each drawn from the same pathogen
distribution) smooths the variability in transition timing, though the distribution of immune responses is bimodal
(c, inset). CI: chronic inflammation (d) The distribution of transition times to chronic inflammation is concentrated
at earlier times (on average after 76 infections). (e) The accumulation of memory cells (blue) and depletion of naive
cells (black) drives immune fragility and vulnerability to new pathogen shapes (50 infection sequences shown). These
figures are generated with the parameters given in Table 3, and with randomly generated pathogen sequences as
described in Eq. 1.
and 7, the system is initialized with zero memory cells Mi(0) = 0 and a uniform distribution of naive cells
Ni(0) = 200 across all possible pathogen shapes i = 1, 2, . . . , Smax.
There are four important timescales in the IIB model: the time τinfec required for pathogen clearance,
the interval ∆T between infection events, and the timescales of naive and memory cell homeostasis control.
Pathogen clearance is the fastest process, during which the homeostasis control still has little effect. The
timescales of naive and memory cell homeostasis are characterized by the reciprocal of their decay rates, given
by 1/δN and 1/δM , respectively. Due to the longevity of immune memory, the interval between infections
∆T was chosen to be much shorter than the timescale of memory decay. Additionally, as in Stromberg
and Carlson naive cells are assumed to regenerate and equilibrate quickly relative to the rate at which
infection events occur [30]. Thus, between infection events the homeostatic naive cell population depends
on a slowly-decaying memory population. More explicitly, the four timescales in IIB model are chosen to
satisfy τinfec < 1/δN < ∆T  1/δM .
Over the course of an infection sequence, early infection events (e.g. before the 50th infection event) are
successfully cleared by the immune system, and the system returns to the health steady state. However, for
later infection events the system fails to recover and instead transitions to the chronic inflammation steady
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state, where it remains thereafter. This age-driven, history-dependent transition to chronic inflammation is
qualitatively similar to “inflammaging.”
Depending on the details of the infection sequence, the timing of the onset of chronic inflammation is
highly variable. Two instances of the transition to chronic inflammation, with different sequences of pathogen
encounters generated from the same statistical distribution of pathogen frequencies, are displayed in Fig. 5a
and Fig. 5b. The strengths of the adaptive (purple) and innate (green) responses during each infection event
are plotted in Fig. 5a and Fig. 5b, quantified by the average number of effector cells 〈E〉 and average number
of phagocytes 〈N∗〉 over the course of each infection, respectively. For the `th infection,
〈E〉 ≡ 1
∆T
∫ t`+1
t`
| ~E(t)| dt, and
〈N∗〉 ≡ 1
∆T
∫ t`+1
t`
N∗(t) dt,
(2)
where | ~E(t)| ≡∑Smaxi=1 Ei(t), and t` is the starting time of the `th infection event. Once the system assumes
the chronic inflammation steady state, the heightened inflammatory response limits the activity of the
adaptive response, and accordingly leads to the sharp transition behavior of the two trajectories observed in
Fig. 5a and 5b. Thus, the onset of chronic inflammation causes the innate response to strengthen while the
adaptive response weakens.
When averaged over an ensemble of infection sequences, variability in the timing of the sharp transition
from health to chronic inflammation smooths into the crossing displayed in Fig. 5c (though the actual
distribution of effector cells and phagocytes across infection sequences is bimodal, as seen in the inset of
Fig. 5c). This crossing behavior is consistent with a longitudinal study of Swedish people, in which middle-
aged people exhibited steady lymphocyte and neutrophil counts over the three-year span of the study, while
older people (>85 years of age) exhibited significantly increased neutrophil counts and significantly decreased
lymphocyte counts over the same span [50]. In addition, people with an immune risk phenotype (IRP) (which
often precedes immune decline and death) commonly possess a weakened adaptive immune repertoire and
experience inflammaging [23]. Taking 〈E〉 and 〈N∗〉 as proxies for adaptive and innate immune function,
the age-dependent transition in the IIB model resembles the shift in immune function experienced by people
with an IRP.
The number of infection events that are encountered before chronic inflammation is reached is plotted as
a distribution across 10,000 randomly-generated infection sequences in Fig. 5d. The distribution in Fig. 5d
decays approximately exponentially for large numbers of infection events. Different choices of pathogen
shape distributions result in different distributions of transition times that are qualitatively similar but in
general not exponentially distributed, as demonstrated in Fig. S1. Thus, the sequence of infection events is
a significant driver of variability in the timing of the transition to chronic inflammation.
To identify the relationship between an infection sequence and the transition from health to chronic
inflammation, we examine the effect of accumulated pathogen exposures on the bulk immune state variables
| # »M | ≡ ∑Smaxi=1 Mi and | #»N | ≡ ∑Smaxi=1 Ni; see Fig. 5e. Over the course of an infection sequence, memory
cells are generated in response to new pathogen encounters at a faster rate than their decay. When fewer
novel pathogens are encountered, memory accumulation slows, since previously encountered pathogens are
cleared more quickly and adaptive immune cells are stimulated for a shorter amount of time. As the
memory cell repertoire grows, the naive cell population shrinks according to the homeostatic constraints.
Eventually, the immune system is unable to defend against novel pathogens because of the depleted naive
cell population. Once this fragility is developed, chronic inflammation will be triggered when any novel
pathogen is encountered.
3.4. The transition to chronic inflammation is influenced by previous pathogen encounters
The disparate immunological outcomes of different individuals demonstrated in Fig. 5 are necessarily
determined by the difference in their infection sequences, since the model equations in Table 2 are otherwise
deterministic. Until the transition to chronic inflammation, the system always returns to the health steady
state. In the health steady state most immune variables assume values that are independent of previous
pathogen encounters; only the naive and memory cell populations occupy values that are potentially different
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Figure 6: Transition to chronic inflammation (CI) is driven by depletion of naive cells and lack of
protection from memory cells. (a) The number of cognate T cells specific to a novel pathogen shape (equal
to the sum of naive and memory cells) is the key indicator for whether an infection event will trigger the chronic
inflammation steady state. Here, cognate T cell counts specific to an encountered pathogen P` are plotted for each
infection event ` across 20 infection sequences sampled from Eq. (1). The color of each point indicates the number of
times that the encountered pathogen P` has been previously encountered. The colored bands are generated from 1000
infection sequences, and envelope the observed cognate cell counts. The large red circles in the lower-right corner
mark the infections events that trigger chronic inflammation across all 1000 infection sequences, which occur when
a novel pathogen is encountered after naive cells have been depleted below some threshold. A shorter time interval
between pathogen encounters of the same shape results in less memory cell decay and hence more cognate T cells,
and this effect causes the shape of the colored bands. (b) We consider three synthetic reorderings of each “authentic”
randomly generated pathogen sequence: the clustered sequence orders pathogens according to their prevalence; the
cyclic sequence orders them to ensure immediate exposure to all pathogen types; and the incomplete cyclic sequence
induces fragility by quickly depleting naive cells and then introducing a novel pathogen. (c) The authentic sequence
and three synthetic sequences transition to chronic inflammation (CI) at different times (black crosses). The pathogen
shape distribution for this infection history (right histogram) is drawn from the theoretical shape distribution (black
line overlaid) given by Eq. (1). (d) The naive cell pool is depleted at different rates depending on how infection events
are ordered. Naive cell counts and their variation across the 50 authentic sequences considered in panel (a) are shown
for the three synthetic sequences. Error bars for the timing of chronic inflammation are 50% confidence intervals.
after each infection event. Therefore different infection sequences lead to differences in memory and naive
cell populations, which in turn are directly responsible for the transition to chronic inflammation.
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In Fig. 6a, the number of cognate T cells (the sum of pathogen-specific naive and memory cells NS`+MS`)
at the beginning of each infection event ` are plotted for 1000 infection sequences, each consisting of 100
infection events sampled from the pathogen shape distribution Eq. (1). Due to the accumulation of immune
memory, the number of cognate T cells specific to a pathogen shape will be greater if that pathogen has
been previously encountered. To demonstrate this, the colored points in Fig. 6a encode the number of times
that a pathogen shape S` was encountered in the ` − 1 previous infection events. A shorter time interval
between infections of the same pathogen shape leads to less memory decay and more cognate T cells specific
to that pathogen, as shown in the black trajectories in Fig. 6a. The average time before a pathogen shape
is re-encountered is randomly distributed, which causes the variability of each color band (computed from
1000 simulated infection sequences). The number of cognate cells specific to novel pathogens is plotted in
blue: in this case no pathogen-specific memory cells exist, and so the cognate cell and naive cell counts are
the same. Therefore, the decline in the dark blue dots demonstrates the gradual decay of naive cell counts
over the course of an infection sequence.
The infection events that trigger the transition to chronic inflammation are indicated by the red circles in
Fig. 6a. These transitions always occur (i) in response to a novel pathogen shape (red circles are laid on top
of the blue band), and (ii) when the number of cognate naive cells falls below a threshold (approximately 180
in Fig. 6a). When both conditions are met, the adaptive immune response is low in magnitude and unable
to produce sufficient anti-inflammatory cytokines to suppress the innate immune branch. This weakened
adaptive immune response, itself a function of the infection sequence, is the principal driver of chronic
inflammation in the IIB model. Accordingly, the IIB model exhibits a “robust yet fragile” behavior [30, 51]:
it is robust to frequently-encountered pathogens, yet fragile to novel pathogens.
3.5. Manipulating immune system fragility via synthetic infection sequences
To probe the variability in the timing of the transition to chronic inflammation, we examine three
synthetic infection sequences that are reorderings of an “authentic” infection sequence sampled from Eq. (1).
These sequences, showcased schematically in Fig. 6b and detailed in the text below, deliberately structure
the order of pathogen encounters to induce different levels of fragility towards novel pathogen shapes. The
synthetic and authentic infection sequences affect the rate of memory cell accumulation and naive cell loss,
and in turn, alter the timing of the onset of chronic inflammation. An example authentic sequence, along
with its corresponding synthetic sequences, is illustrated in Fig. 6c. In Fig. 6d naive cell statistics of 50
authentic infection sequences are compared with the statistics generated by their synthetic counterparts.
In the clustered synthetic ordering (Fig. 6b-d, orange), the infection sequence is ordered so that the
most common pathogens are encountered first and the rarest pathogens are encountered last. In this case,
pathogens are immediately reencountered so memory cells do not significantly decay between infections, and
the accumulated immune memory causes an accelerated immune response that generates fewer memory cells.
Therefore, this reordering is a lower bound for the naive cell loss rate. Indeed, the clustered sequence leads
to the slowest loss of naive cells among the authentic and synthetic sequences in Fig. 6d. The clustered
sequence provides reliable protection that delays the transition to chronic inflammation until infection 89,
compared with the authentic sequence that transitions after infection 66, as shown in Fig. 6c.
In the cyclic synthetic ordering (Fig. 6b-d, yellow) infections are ordered so that all available pathogen
types are encountered as early as possible: in this ordering each pathogen type is encountered once before
any pathogen is encountered for the second time, then each pathogen type is encountered twice before any
pathogen is encountered for the third time, and so on. Constantly encountering new pathogen types drives
the accumulation of memory cells and in turn naive cell loss at an accelerated rate. Thus the cyclic sequence
yields an upper bound for the naive cell loss rate, as in Fig. 6d. At the same time, since this synthetic
sequence is structured to front-load every pathogen type that can be encountered early in the infection
history, the generated memory cells eventually provide full protection against each pathogen type, and the
chronic inflammation state never occurs, as in Fig. 6c. Thus, broad exposure to pathogens early in an
individual’s infection life history can provide adaptive-mediated protection from chronic inflammation in the
IIB model.
Lastly, the incomplete cyclic synthetic ordering (Fig. 6b-d, purple) is similar in construction to the cyclic
ordering, except that one rare pathogen is intentionally omitted from the initial pathogen cycles. Then, this
pathogen is presented at a later time to trigger chronic inflammation. The incomplete cyclic ordering induces
a fragile immune response: naive cells deplete nearly as quickly as for the cyclic ordering, and incomplete
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Figure 7: Effector cells are subject to a trade-off between clearing pathogens and suppressing inflam-
mation. (a) The onset of chronic inflammation (histograms as in Fig. 6d) is delayed for lower values of p, i.e. when
the anti-inflammatory role of effector cells is increased. (b) The cumulative pathogen load L` over the course of each
infection event (averaged over 1000 infection sequences) is larger for smaller values of p. The drop in L` after the 60th
infection event for p = 0.9 is caused by the onset of chronic inflammation, which compensates for the overspecialized
adaptive immune repertoire. To generate the statistics in panel (a), the homeostatic parameters δN , δM , R0, and θN
were modified to ensure that the timescales of infection clearance and homeostatic response were separated enough
for us to use the adaptive programming method, as described in Table S1 of the Supplementary Information. The
simulations in panel (b) are generated with the parameters given in Table 3.
.
immune memory coverage causes vulnerability to novel pathogens. Thus, the onset of chronic inflammation
is accelerated in the incomplete cyclic ordering, with the onset occurring during the 48th infection in Fig. 6c.
The clustered and cyclic synthetic immune histories demonstrate how some pathogen sequences can
delay the onset of chronic inflammation, either by prolonging the abundance of naive cells or by quickly
acquiring full immune memory coverage across all pathogen shapes. In contrast, the incomplete cyclic
sequence demonstrates how pathogen sequences can induce immune fragility, by quickly depleting naive cells
while remaining vulnerable to novel pathogens; alternatively, the incomplete cyclic sequence shows how the
introduction of a new pathogen species, either through mutation or migration to a new environment, can
break existing memory coverage and lead to immune fragility.
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3.6. The adaptive immune response is subject to a trade-off between pathogen clearance and suppressing
inflammation
In the original adaptive immune model by Stromberg and Carlson [30], the sole function of effector
cells was to clear pathogens. However, the diverse repertoire of effector T cells— including helper T cells,
cytotoxic T cells, and regulatory T cells— can additionally exhibit anti-inflammatory functions [13, 17,
52]. Incorporating these features in the IIB model leads to a trade-off between pathogen clearance and
inflammation suppression that can be explored quantitatively.
Specifically, in the IIB model a proportion p of effector cells are allocated to pathogen clearance (a
responsibility of cytotoxic T cells with the aid of helper T cells [53]), while a proportion 1−p of effector cells
are allocated to the production of anti-inflammatory cytokines (a responsibility of regulatory T cells [52]).
These dual functions are presented schematically in Fig. 1 and explicitly in Table 2.
For smaller values of p, effector cells are increasingly used to combat inflammation, which delays the
onset of chronic inflammation as demonstrated in Fig. 7a. On the other hand, at smaller values of p more
resources are allocated to combat inflammation, so the diminished innate response slows the rate of pathogen
clearance. This is quantified in Fig. 7b, which plots an ensemble average (across 1000 infection sequences)
of the cumulative pathogen load L` for each infection event: for the `th infection,
L` ≡
∫ t`+1
t`
PS`(t) dt, (3)
where S` is the pathogen shape and t` the starting time of the `th infection event. This measure was
originally introduced in Stromberg and Carlson [30] where it was called the “loss function,” and we similarly
use it here as a proxy for the damage the pathogen inflicts during each infection event. In Fig. 7b, smaller
values of p lead to greater cumulative pathogen load for each infection event and vice versa.
Note that for p as large as 0.9 there is a further drop in L` for ` & 60 due to the onset of the chronic
inflammation steady state in a larger proportion of individuals. Once the chronic inflammation state is
reached, the non-zero activated phagocyte population N∗ rapidly responds to infection events, efficiently
clears pathogens, and returns to the chronic inflammation steady state. In this sense, the onset of chronic
inflammation acts as a protective mechanism that shields the immune response from future pathogen en-
counters and minimizes the damage that pathogen inflicts. Interpreted biologically, it is advantageous for
organisms to minimize cumulative pathogen load while also avoiding the early onset of chronic inflammation.
Evolutionarily, these two opposing selection forces should lead to an intermediate optimal p in which effector
cells allocate resources both to pathogen clearance and innate suppression.
4. Discussion
4.1. Immunosenescence as an emergent immune response
Though immunosenescence affects every aging individual, the mechanisms through which it develops are
not yet fully understood. In this paper we demonstrate through quantitative modeling how physiological
markers of immunosenescence can arise from the accumulated effect of pathogen encounters. In particular,
clonal expansion and homeostatic maintenance lead to an increase in memory cells and a decrease in naive
cells, which are qualitatively consistent with their clinically-observed abundances [28]. Accumulated memory
cells protect the immune system against previously-encountered pathogens, but the shrinkage in the naive
cell pool renders the immune system vulnerable to novel pathogens and is the key indicator of immune
system fragility. While a similar mechanism was demonstrated in the model by Stromberg and Carlson [30],
in their study the overspecialized immune repertoire led to increased cumulative pathogen load. In the IIB
model, the acquired immune fragility is characterized by a transition to a chronic inflammatory state, and
the timing of this transition is highly variable and depends on the infection history.
In addition to this mechanism of imbalanced immunological space, several other immune functions vary
with age and could play a role in the development of immunosenescence. For example, clinical studies
observed that the average cytotoxicity of natural killer cells decreases with age [54, 55], cell signaling between
immune cells can become impaired with age [56], and thymus involution leads to decreased T cell production
with age [57, 58]. The current formulation of the IIB model exhibits an inflammaging-like behavior without
taking these additional factors into account. However, in future work physiological parameters of the model
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could be used as a proxy for these observed behaviors: for example, the decreased cytotoxicity of natural
killer cells (which are innate) could be incorporated by decreasing kpn with age, the impaired cell signaling in
T cells (which are adaptive) could be achieved by decreasing γ with age, or the reduced thymus output could
be modeled by decreasing θN with age. The calculated immune outcomes that result from these modifications
could shed light on the relative contributions to immunosenescence from memory-induced fragility in the
adaptive response, an impaired innate response, and an impaired adaptive response.
4.2. Chronic inflammation as inflammaging and the collaboration between innate and adaptive responses
The chronic inflammation steady state has two physiological interpretations. First, the runaway tissue
damage caused by the sustained inflammatory response may cause death in the host, as was implied by
Reynolds et al. when they called this steady state “aseptic death.” Second, if the sustained inflammatory
response is relatively minor, the chronic inflammation state can be interpreted as “inflammaging,” a chronic
low-grade inflammation that is common among the elderly [24]. In this paper we choose this second inter-
pretation and construe the transition to the chronic inflammation state as inflammaging. Accordingly, the
mechanisms of the IIB model that induce this transition might inform the biological mechanisms that they
emulate.
For example, recent work has suggested that the development of inflammaging might be a result of
immune system remodeling: as immunosenescence lessens the efficacy of the adaptive immune response,
the body relies on inflammaging for protection against pathogens via the innate immune response [28].
Similarly, the adaptive response in the IIB model is subject to a trade-off between clearing pathogens and
suppressing inflammation. In part based on recent work demonstrating that the adaptive response can act to
suppress a hazardous innate response [17], recent theories suggest that this suppression might have been the
evolutionary driver that promoted the development of an adaptive immune response [16]. Similarly, in the
IIB model when pathogens are introduced to a system in the chronic inflammation state, they are cleared
almost immediately since the inflammatory response is already primed.
Evolutionarily, the innate immune response preceded the creation of the adaptive response [59]. This is
consistent with the taxonomic complexity of organisms, in which invertebrates possess only an innate response
while vertebrates possess the additional capacity for pathogen-specific immune memory [60]. Additionally,
adaptive immune components are dependent on innate cells— for example, the activation of an adaptive
response through antigen presentation relies on dendritic cells. The evolutionary drivers of the adaptive
immune response could be explored with immune models that quantify the added benefit of possessing an
adaptive immune system.
4.3. Age-dependent strength of immune response
The efficiency of the human immune system changes in a non-monotonic manner as one ages: it is weak in
infancy and dependent on maternal antibodies; then it grows stronger as the innate and adaptive responses
mature and as immune memory is accumulated; and finally it plummets in the elderly [61]. As people age,
effector T cell levels drop, chronic inflammation builds [23, 62], and immune outcomes among the elderly
become extremely variable [62].
In this work we present a potential mechanism for these clinically-observed aging trends, driven by over-
specialization of the adaptive immune repertoire. The accumulation of memory cells initially strengthens
the immune response against previously-encountered pathogens. Eventually, memory cells become overspe-
cialized and restrict the growth of naive cells, rendering aged individuals vulnerable to rare pathogen types.
In the IIB model the onset of the chronic inflammation state is variable, and dependent on the history of
previous pathogen encounters. The age-dependent immune system efficiency observed in the IIB model is
consistent with the previously mentioned clinically-observed immune behaviors.
4.4. Imprinting and vaccines
Lastly, the shape space formulation of the adaptive immune response produces results that are quali-
tatively similar to the clinically-observed behaviors of immune imprinting [63] and the decreased efficacy
of vaccines in the elderly [55]. Immune imprinting occurs when individuals exhibit sustained memory to
the pathogens they were exposed to early in their life. In the IIB model naive cells are more abundant at
the beginning of an infection sequence, and as memory cells accumulate over time, homeostatic pressures
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drive down the population of naive cells. Thus, during the first several infection events the larger naive cell
pool will induce a stronger adaptive response and therefore generate a stronger memory for encountered
pathogens. On the contrary, near the end of an infection sequence the diminished naive pool will induce a
weaker adaptive response to a novel pathogen, and generate a weaker immune memory. If we interpret vacci-
nation as an exposure to a novel pathogen, then the clinically-observed characteristics of immune imprinting
and vaccination in the elderly are qualitatively captured by the IIB model.
5. Conclusion
The progression towards immunosenescence is a dynamical process influenced by a lifetime of pathogen
encounters, physiological alterations, genetic factors, and general lifestyle choices. This blend of factors
makes it difficult to isolate and identify the most relevant causative agents of immunosenescence. Therefore,
mathematical models hold great utility in their ability to probe the causes of immunosenescence.
In this paper we developed the IIB model, which incorporates the structure of the innate and adaptive
immune branches, and exhibits behaviors that are qualitatively consistent with clinically-observed phenom-
ena. We found that repeated pathogen encounters cause the overspecialization of memory cells and the
depletion of naive cells, and over time these effects render the immune system vulnerable to novel pathogens.
By describing immune dynamics with a mathematical model, we demonstrated how feedbacks between the
innate and adaptive immune responses could give rise to variable immune courses and outcomes. Going
forward, experimental studies combined with quantitative immune models will continue to illuminate the
mechanisms of immunosenescence.
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